Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding

Bulletin Express07-03

Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month.

The authorised share capital stayed at 2.00 billion ordinary shares with a par value of USD 0.0001, representing USD 0.20 million in registered share capital.

Issued share capital remained flat at 1.30 billion ordinary shares, and the company held no treasury shares. Clover affirmed compliance with Hong Kong’s minimum public-float requirement of 25 percent.

Option activity was inactive in June. Outstanding options totalled 43.98 million shares, comprising 1.46 million under the Pre-IPO Share Option Plan and 42.52 million under the Post-IPO Share Option Plan. The Post-IPO scheme still allows an additional 72.24 million shares to be granted. No options were exercised, cancelled, or lapsed, and no funds were raised from option exercises.

The company reported no warrants, convertibles, or other equity-linked instruments in issue and confirmed full compliance with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198338149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198338149","market":"hk","top_or_hot":-1,"title":"Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding","media":"Bulletin Express","content":"<p>Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month.</p>\n<p>The authorised share capital stayed at 2.00 billion ordinary shares with a par value of USD 0.0001, representing USD 0.20 million in registered share capital.</p>\n<p>Issued share capital remained flat at 1.30 billion ordinary shares, and the company held no treasury shares. Clover affirmed compliance with Hong Kong’s minimum public-float requirement of 25 percent.</p>\n<p>Option activity was inactive in June. Outstanding options totalled 43.98 million shares, comprising 1.46 million under the Pre-IPO Share Option Plan and 42.52 million under the Post-IPO Share Option Plan. The Post-IPO scheme still allows an additional 72.24 million shares to be granted. No options were exercised, cancelled, or lapsed, and no funds were raised from option exercises.</p>\n<p>The company reported no warrants, convertibles, or other equity-linked instruments in issue and confirmed full compliance with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month.</p>\n<p>The authorised share capital stayed at 2.00 billion ordinary shares with a par value of USD 0.0001, representing USD 0.20 million in registered share capital.</p>\n<p>Issued share capital remained flat at 1.30 billion ordinary shares, and the company held no treasury shares. Clover affirmed compliance with Hong Kong’s minimum public-float requirement of 25 percent.</p>\n<p>Option activity was inactive in June. Outstanding options totalled 43.98 million shares, comprising 1.46 million under the Pre-IPO Share Option Plan and 42.52 million under the Post-IPO Share Option Plan. The Post-IPO scheme still allows an additional 72.24 million shares to be granted. No options were exercised, cancelled, or lapsed, and no funds were raised from option exercises.</p>\n<p>The company reported no warrants, convertibles, or other equity-linked instruments in issue and confirmed full compliance with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1198338149","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198338149","pubTimestamp":1783070663,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month. The authorised share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"Clover Biopharma报告6月份股价没有变化；仍有13亿股流通股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month.\nThe authorised share capital stayed at 2.00 billion ordinary shares with a par value of USD 0.0001, representing USD 0.20 million in registered share capital.\nIssued share capital remained flat at 1.30 billion ordinary shares, and the company held no treasury shares. Clover affirmed compliance with Hong Kong’s minimum public-float requirement of 25 percent.\nOption activity was inactive in June. Outstanding options totalled 43.98 million shares, comprising 1.46 million under the Pre-IPO Share Option Plan and 42.52 million under the Post-IPO Share Option Plan. The Post-IPO scheme still allows an additional 72.24 million shares to be granted. No options were exercised, cancelled, or lapsed, and no funds were raised from option exercises.\nThe company reported no warrants, convertibles, or other equity-linked instruments in issue and confirmed full compliance with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198338149","isCrawlerRequest":true}